MONIVENT AB
NNGM:MONI0.17
SEK
+0.01
(+3.75%)
ISIN
SE0013512282
Return %
Stock
S&P 500
1Y
-56.08
14.20
3Y
-83.08
81.12
5Y
-98.35
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Maria Lindqvist
- Full Time Employees
- 4
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Gothenburg Sweden
- IPO Date
- Mar 17, 2020
- Website
- monivent.se
- Similar Companies
- Business
- Monivent AB is a Swedish medical technology company that develops, manufactures, and commercializes medical device and training solutions designed to improve manual respiratory support and resuscitation for newborn infants. Founded in 2013 and headquartered in Gothenburg, Sweden, the company operates within the healthcare equipment and neonatal care sector, serving clinical maternity departments, delivery suites, neonatal intensive care units, and medical simulation centers across Europe, North America, and other international markets. Monivent AB's proprietary technology provides real-time, objective feedback on ventilation parameters to assist healthcare professionals in delivering safe, precise tidal volumes and preventing lung and brain injuries in vulnerable newborns. The company's primary product and service offerings comprise: Monivent Neo100, a clinical monitoring system designed for delivery room and intensive care use that provides real-time objective data during newborn resuscitation by measuring expiratory tidal volume, peak inspiratory pressure, positive end-expiratory pressure, ventilation rate, and mask leakage; Monivent Neo Training, a specialized simulation training device and software system used on neonatal manikins for medical education and clinical skill development; wireless sensor modules, compact units that integrate directly between the resuscitation device and face mask to capture and wirelessly transmit airflow and pressure data; dedicated display monitors and proprietary analytics software, delivering color-coded visual guidance, target range feedback, and post-session performance reviews; charging stations and docking accessories for sensor management; and consumable accessories, including single-use sensor adapters, face masks, and clinical connection cables. In recent developments, Monivent AB secured European Union Medical Device Regulation certification for its flagship Monivent Neo100 system, establishing full regulatory clearance for clinical commercialization across the European market. The company also executed key executive leadership transitions, appointing Tobias Tullberg as Chief Executive Officer to drive commercial scaling and international market adoption. To broaden global market penetration, Monivent AB maintains strategic commercial alliances, including a distribution partnership with Draeger for the roll-out of the Neo100 system in Europe, an agreement with Echo Healthcare Inc. for the distribution of Monivent Neo Training in the United States and Canada, and regional distribution agreements with partners such as MDT Global Solutions in the United Kingdom and Ireland, MedCare Visions GmbH in Germany, and Anandic Medical Systems AG in Switzerland. Additionally, the company completed corporate restructuring and capital-raising initiatives through directed share issues and rights offerings to strengthen its balance sheet and fund ongoing commercial rollout and international clinical adoption.